세계의 세포 및 유전자 치료 CDMO 시장(2024년판) : 유형별, 용도별, 적응증별, 지역별, 국가별 분석, 시장 인사이트 및 예측(2024-2029년)

Executive Summary

Azoth Analytics has released a research report titled "Global Cell and Gene Therapy CDMO Market (2024 Edition)" which provides a complete analysis of the Global Cell and Gene Therapy CDMO Market industry in terms of market segmentation by Type (Cell Therapy, Gene Therapy, Gene-modified Cell Therapies), Application (Clinical, Pre-clinical), Indication (Oncology Diseases, Infectious Diseases, Neurological Disorder, Others) for the historical period of 2019-2022, estimates of 2023 and the forecast for 2024-2029.

The Global Cell and Gene Therapy CDMO market valued at USD 2.54 billion in 2022 is expected to grow at a CAGR of 30.75% during the forecast period of 2024-2029. The global Cell and Gene Therapy CDMO market has been experiencing robust growth and escalating demand, propelled by continuous advancements in cell and gene therapies. With a broadening scope of therapeutic areas and a favourable regulatory environment, the global Cell and Gene Therapy CDMO market is poised for sustained expansion as it plays a pivotal role in the development and commercialization of ground-breaking therapies for various diseases. The global Cell and Gene Therapy CDMO market is expected to grow at an extraordinary rate driven by significant investments from industry players.

The global pipeline of cell and gene therapies has been expanding, covering a wide range of therapeutic areas, including oncology, rare diseases, and genetic disorders. As more therapies advance through clinical trials and toward commercialization, the demand for CDMO services for manufacturing, process development, and scale-up increases.

Global CDMO organisations for cell and gene therapy are expanding, and this is one of the main factors propelling the global Cell and Gene Therapy's overall expansion. With the increasing global demand for advanced cell and gene therapies, CDMOs are proactively setting up production facilities in various locations to meet the changing demands of biotechnology and pharmaceutical companies. These days, CDMOs are essential to the manufacturing of pharmaceuticals. Over the past ten years, CDMOs have grown in prominence due to a more dynamic mergers and acquisition landscape. Serving both local and international markets, there are currently over 600 active Contract Development and Manufacturing Organizations (CDMOs). CDMOs provide specific expertise that helps both "Big Pharma" and smaller inventors to launch products sooner.

The rise of biologics is seen by the number of CDMOs making significant investments in brand-new biomanufacturing facilities. These companies include Boehringer Ingelheim (USD827M investment), Samsung Biologics (USD1.7B investment), Lonza (USD935M expansion), and Fujifilm Diosynth Biotechnologies (USD2B investment).

Additionally, by expanding globally, CDMOs can meet regional regulatory needs, provide customised manufacturing solutions, and improve accessibility for customers who need their services. CDMOs can provide more adaptable and responsive solutions by being present in important worldwide markets. This helps to speed up the development and global commercialization of gene and cell therapies.

One prominent factor restraining the growth of the global Cell and Gene Therapy CDMO market is the high cost of producing viral vectors. As carriers of therapeutic genes into target cells, viral vectors are essential to the development of gene and cell therapies. Viral vector production is a complex procedure that frequently involves specialized techniques, stringent quality control standards, and specialized facilities.

There are now five viral vectors in use for gene therapy. AAV have the biggest market share, followed by lentiviruses, adenoviruses, herpes simplex viruses and retroviruses. The vector manufacturing cost for a single dose might be as high as USD 1-2 million, given the expected price of USD 3-7 million per batch, according to Roland Berger Insights. Therefore, the high cost of producing viral vectors hampers cell and gene therapies from being widely commercialised and made accessible, which limits their uptake and hinders the expansion of the Cell and Gene CDMO market.

Scope of the Report

• The report analyses the Global Cell and Gene Therapy CDMO Market by Value (USD Million).
• The report presents the analysis of Global Cell and Gene Therapy CDMO Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the Global Cell and Gene Therapy CDMO Market by Type (Cell Therapy, Gene Therapy, Gene-modified Cell Therapies).
• The report analyses the Cell and Gene Therapy CDMO Market by Application (Clinical, Pre-clinical).
• The report analyses the Cell and Gene Therapy CDMO Market by Indication (Oncology Diseases, Infectious Diseases, Neurological Disorder, Other Indications).
• The report analyses the Cell and Gene Therapy CDMO Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa).
• The report analyses the Cell and Gene Therapy CDMO Market by Country (United States, Canada, United Kingdom, Germany, France, Italy, China, Japan, South Korea, India).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis.
• Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Oxford Biomedica, Lonza Group AG, Catalent, Inc., Samsung Biologics, WuXi Biologics, Pfizer CentreOne, Danaher Corporation, Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., Novartis AG.

Table of Contents

1. Market Background

• 1.1 Scope and Product Outlook
• 1.2 Executive Summary
• 1.3 Research Methodology

2. Strategic Recommendations

3. Global Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

• 3.1 Impact Analysis of Macro Economic Factors on Cell and Gene Therapy CDMO Market
• 3.2 Cell and Gene Therapy Pipeline
• 3.3 Clinical AAV Gene Therapies
• 3.4 Approvals & Drugs by Therapy Area
• 3.5 Approved Therapies and Pipeline
• 3.6 Gene Therapy Pipeline
• 3.7 Gene Therapy Breakdown
• 3.8 Gene Therapy Pipeline: Most Commonly Targeted Therapeutic Areas
• 3.9 Cell and Gene Therapy Landscape
• 3.10 Global Cell and Gene Therapy CDMO Market: Dashboard
• 3.11 Global Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million)
• 3.12 Global Cell and Gene Therapy CDMO Market: Recent Development & Approved Cell and Gene Therapies
• 3.13 Global Cell and Gene Therapy CDMO Market: Recent M&A and Developments
• 3.14 Impact of COVID-19 on Cell and Gene Therapy CDMO Market
• 3.15 Global Cell and Gene Therapy CDMO Market Segmentation: By Type
  • 3.15.1 Global Cell and Gene Therapy CDMO Market, By Type Overview
  • 3.15.2 Global Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.15.3 Global Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.15.4 Global Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
• 3.16 Global Cell and Gene Therapy CDMO Market Segmentation: By Application
  • 3.16.1 Global Cell and Gene Therapy CDMO Market, By Application Overview
  • 3.16.2 Global Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.16.3 Global Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
• 3.17 Global Cell and Gene Therapy CDMO Market Segmentation: By Indication
  • 3.17.1 Global Cell and Gene Therapy CDMO Market, By Indication Overview
  • 3.17.2 Global Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.17.3 Global Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.17.4 Global Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.17.5 Global Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)

4. Global Cell and Gene Therapy CDMO Market: Regional Analysis

• 4.1 Regional Coverage of the Study
• 4.2 Regional Snapshot

5. Americas Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

• 5.1 Americas Cell and Gene Therapy CDMO Market: Snapshot
• 5.2 Americas Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
• 5.3 Americas Cell and Gene Therapy CDMO Market: Key Factors
• 5.4 Americas Cell and Gene Therapy CDMO Market: Segment Analysis
• 5.5 Americas Cell and Gene Therapy CDMO Market Segmentation: By Type
  • 5.5.1 Americas Cell and Gene Therapy CDMO Market, By Type Overview
  • 5.5.2 Americas Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.5.3 Americas Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.5.4 Americas Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
• 5.6 Americas Cell and Gene Therapy CDMO Market Segmentation: By Application
  • 5.6.1 Americas Cell and Gene Therapy CDMO Market, By Application Overview
  • 5.6.2 Americas Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.6.3 Americas Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
• 5.7 Americas Cell and Gene Therapy CDMO Market Segmentation: By Indication
  • 5.7.1 Americas Cell and Gene Therapy CDMO Market, By Indication Overview
  • 5.7.2 Americas Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.7.3 Americas Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.7.4 Americas Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.7.5 Americas Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
• 5.8 Americas Cell and Gene Therapy CDMO Market Segmentation: By Country
  • 5.8.1 Americas Cell and Gene Therapy CDMO Market, By Country Overview
  • 5.8.2 United States Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 5.8.2.1 United States Cell and Gene Therapy CDMO Market, By Type
    • 5.8.2.2 United States Cell and Gene Therapy CDMO Market, By Application
    • 5.8.2.3 United States Cell and Gene Therapy CDMO Market, By Indication
  • 5.8.3 Canada Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 5.8.3.1 Canada Cell and Gene Therapy CDMO Market, By Type
    • 5.8.3.2 Canada Cell and Gene Therapy CDMO Market, By Application
    • 5.8.3.3 Canada Cell and Gene Therapy CDMO Market, By Indication
  • 5.8.4 Rest of Americas Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 5.8.4.1 Rest of Americas Cell and Gene Therapy CDMO Market, By Type
    • 5.8.4.2 Rest of Americas Cell and Gene Therapy CDMO Market, By Application
    • 5.8.4.3 Rest of Americas Cell and Gene Therapy CDMO Market, By Indication

6. Europe Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

• 6.1 Europe Cell and Gene Therapy CDMO Market: Snapshot
• 6.2 Europe Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
• 6.3 Europe Cell and Gene Therapy CDMO Market: Key Factors
• 6.4 Europe Cell and Gene Therapy CDMO Market: Segment Analysis
• 6.5 Europe Cell and Gene Therapy CDMO Market Segmentation: By Type
  • 6.5.1 Europe Cell and Gene Therapy CDMO Market, By Type Overview
  • 6.5.2 Europe Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.5.3 Europe Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.5.4 Europe Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
• 6.6 Europe Cell and Gene Therapy CDMO Market Segmentation: By Application
  • 6.6.1 Europe Cell and Gene Therapy CDMO Market, By Application Overview
  • 6.6.2 Europe Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.6.3 Europe Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
• 6.7 Europe Cell and Gene Therapy CDMO Market Segmentation: By Indication
  • 6.7.1 Europe Cell and Gene Therapy CDMO Market, By Indication Overview
  • 6.7.2 Europe Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.7.3 Europe Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.7.4 Europe Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.7.5 Europe Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
• 6.8 Europe Cell and Gene Therapy CDMO Market Segmentation: By Country
  • 6.8.1 Europe Cell and Gene Therapy CDMO Market, By Country Overview
  • 6.8.2 United Kingdom Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.2.1 United Kingdom Cell and Gene Therapy CDMO Market, By Type
    • 6.8.2.2 United Kingdom Cell and Gene Therapy CDMO Market, By Application
    • 6.8.2.3 United Kingdom Cell and Gene Therapy CDMO Market, By Indication
  • 6.8.3 Germany Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.3.1 Germany Cell and Gene Therapy CDMO Market, By Type
    • 6.8.3.2 Germany Cell and Gene Therapy CDMO Market, By Application
    • 6.8.3.3 Germany Cell and Gene Therapy CDMO Market, By Indication
  • 6.8.4 France Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.4.1 France Cell and Gene Therapy CDMO Market, By Type
    • 6.8.4.2 France Cell and Gene Therapy CDMO Market, By Application
    • 6.8.4.3 France Cell and Gene Therapy CDMO Market, By Indication
  • 6.8.5 Italy Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.5.1 Italy Cell and Gene Therapy CDMO Market, By Type
    • 6.8.5.2 Italy Cell and Gene Therapy CDMO Market, By Application
    • 6.8.5.3 Italy Cell and Gene Therapy CDMO Market, By Indication
  • 6.8.6 Rest of Europe Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.6.1 Rest of Europe Cell and Gene Therapy CDMO Market, By Type
    • 6.8.6.2 Rest of Europe Cell and Gene Therapy CDMO Market, By Application
    • 6.8.6.3 Rest of Europe Cell and Gene Therapy CDMO Market, By Indication

7. Asia Pacific Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

• 7.1 Asia Pacific Cell and Gene Therapy CDMO Market: Snapshot
• 7.2 Asia Pacific Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
• 7.3 Asia Pacific Cell and Gene Therapy CDMO Market: Key Factors
• 7.4 Asia Pacific Cell and Gene Therapy CDMO Market: Segment Analysis
• 7.5 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Type
  • 7.5.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Type Overview
  • 7.5.2 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.5.3 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.5.4 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
• 7.6 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Application
  • 7.6.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Application Overview
  • 7.6.2 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.6.3 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
• 7.7 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Indication
  • 7.7.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Indication Overview
  • 7.7.2 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.7.3 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.7.4 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.7.5 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
• 7.8 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Country
  • 7.8.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Country Overview
  • 7.8.2 China Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.2.1 China Cell and Gene Therapy CDMO Market, By Type
    • 7.8.2.2 China Cell and Gene Therapy CDMO Market, By Application
    • 7.8.2.3 China Cell and Gene Therapy CDMO Market, By Indication
  • 7.8.3 Japan Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.3.1 Japan Cell and Gene Therapy CDMO Market, By Type
    • 7.8.3.2 Japan Cell and Gene Therapy CDMO Market, By Application
    • 7.8.3.3 Japan Cell and Gene Therapy CDMO Market, By Indication
  • 7.8.4 South Korea Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.4.1 South Korea Cell and Gene Therapy CDMO Market, By Type
    • 7.8.4.2 South Korea Cell and Gene Therapy CDMO Market, By Application
    • 7.8.4.3 South Korea Cell and Gene Therapy CDMO Market, By Indication
  • 7.8.5 India Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.5.1 India Cell and Gene Therapy CDMO Market, By Type
    • 7.8.5.2 India Cell and Gene Therapy CDMO Market, By Application
    • 7.8.5.3 India Cell and Gene Therapy CDMO Market, By Indication
  • 7.8.6 Rest of Asia Pacific Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.7.1 Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Type
    • 7.8.7.2 Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Application
    • 7.8.7.3 Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Indication

8. Middle East & Africa Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

• 8.1 Middle East & Africa Cell and Gene Therapy CDMO Market: Snapshot
• 8.2 Middle East & Africa Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
• 8.3 Middle East & Africa Cell and Gene Therapy CDMO Market: Key Factors
• 8.4 Middle East & Africa Cell and Gene Therapy CDMO Market: Segment Analysis
• 8.5 Middle East & Africa Cell and Gene Therapy CDMO Market Segmentation: By Type
  • 8.5.1 Middle East & Africa Cell and Gene Therapy CDMO Market, By Type Overview
  • 8.5.2 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.5.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.5.4 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
• 8.6 Middle East & Africa Cell and Gene Therapy CDMO Market Segmentation: By Application
  • 8.6.1 Middle East & Africa Cell and Gene Therapy CDMO Market, By Application Overview
  • 8.6.2 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.6.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
• 8.7 Middle East & Africa Cell and Gene Therapy CDMO Market Segmentation: By Indication
  • 8.7.1 Middle East & Africa Cell and Gene Therapy CDMO Market, By Indication Overview
  • 8.7.2 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.7.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.7.4 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.7.5 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

• 9.1 Impact Assessment of Market Dynamics on Global Cell and Gene Therapy CDMO Market
• 9.2 Drivers
• 9.3 Restraints
• 9.4 Trends

10. Industry Ecosystem Analysis

• 10.1 Value Chain Analysis
• 10.2 Porter's Five Forces Model

11. Competitive Positioning

• 11.1 Companies' Product Positioning
• 11.2 Competitive Positioning of Oxford Biomedica's Viral Vector Offering
• 11.3 Market Position Matrix
• 11.4 Market Share Analysis of Cell and Gene Therapy CDMO Market
• 11.5 Company Profiles
  • 11.5.1 Oxford Biomedica
  • 11.5.2 Lonza Group AG
  • 11.5.3 Catalent, Inc.
  • 11.5.4 Samsung Biologics
  • 11.5.5 WuXi Biologics
  • 11.5.6 Pfizer CentreOne
  • 11.5.7 Danaher Corporation
  • 11.5.8 Thermo Fisher Scientific Inc.
  • 11.5.9 Charles River Laboratories International, Inc.
  • 11.5.10 Novartis AG